BJH - volume 11, issue 2, march 2020
M. Clauwaert MD, V. Galle MD, M. Maerevoet MD, A. Janssens MD, PhD, K. Saevels MD, S. Snauwaert MD, PhD, C. Springael MD, PhD, V. Van Hende MD, G. Verhoef MD, PhD, F. Offner MD, PhD
Follicular lymphoma is the most common low-grade non-Hodgkin lymphoma. Survival rates have been rising over time mainly due to advancing therapeutic strategies. As the last Belgian guidelines date from 2012, we present an update of the scientific evidence regarding diagnosis, staging, treatment and follow-up, and confront these to the Belgian reimbursement rules anno 2019. Follicular lymphoma grade 3B is classified as high-grade lymphoma and treated accordingly, and will not be discussed in this paper. Early stage disease can be treated with involved-field radiotherapy, which has curative potential. Advanced stage disease is virtually incurable, but many treatment options are available with good results. In first line, treatment is mostly based on chemotherapy combined with rituximab; the latter can be continued as maintenance therapy. In relapsed setting, introduction of the newer and more potent anti-CD20-antibody obinutuzumab, also in combination with chemotherapy, can lead to improved survival in high-risk patients. For older patients with comorbidities, rituximab monotherapy is the preferred option. In further lines, PI3K-inhibition with idelalisib and radioimmunotherapy are available. Finally, autologous or allogeneic stem cell transplantation remain an option in a small group of selected patients.
(BELG J HEMATOL 2020;11(2):67–74)
Read moreBJH - volume 9, issue 3, june 2018
V. Galle MD, P. Vlummens MD, F. Offner MD, PhD
Chronic lymphocytic leukaemia has a very heterogeneous disease evolution. Prognostic factors of B-CLL overall survival have been extensively studied. However, much less is known about prognostic factors that can identify patients who will never develop an indication for treatment, at the time of their initial diagnosis. In this study we give an overview of variables that have a predictive value for treatment free survival. Subsequently, we try to develop a novel prognostic index, to address the question ‘who will never need treatment for B-CLL?’.
(BELG J HEMATOL 2018;9(3):124–9)
Read moreBJH - 2018, issue Abstract Book BHS, february 2018
V. Galle MD, P. Vlummens MD, F. Offner MD, PhD
BJH - 2018, issue Abstract Book BHS, february 2018
V. Galle MD, P. Vlummens MD, F. Offner MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
V. Galle MD, S. Verbeke , W. Ceelen , I. Moors MD
BJH - volume 6, issue Abstract Book BHS, january 2015
V. Galle MD, C. De Vriendt , P. Vlummens MD, A. Vantilborgh , D. Benoit MD, PhD, E. De Coster
Top
